Griffith University

DPhil, FRIC (UK)

Professor of Medicine

Biomolecular and Physical Sciences - Adjunct Professor

Contact details for Professor Michael Whitehouse

Biography

Professor Whitehouse has taught Organic Chemistry, Biochemistry, Pharmacology and Pathology to medical students and honours science students in five Universities across the world.

His research interests cover chemistry of natural products; medical aspects of lipid metabolism; mechanisms of actions of anti-inflammatory, corticosteroid and anti-arthritic agents; biochemistry of chronic inflammation; molecular toxicology relating to side-effects of drugs; and evaluation of herbal/complementary medicines.  

Professor Whitehouse currently holds two Griffith University positions, Honorary Professor of Medicine with the School of Medicine and Adjunct Professor of Biomolecular and Physical Sciences.

Research interests   

• Arthritis prevention
• Arthritis treatment - novel therapies
• Nutritional medicine
• Toxicology

Current research projects    

• Therapeutic applications of gold
• Silver pharmacology
• Safety and efficacy of traditional medicines for arthritis

Publications    

Refereed journal articles

• CL Brown, GR Bushell, ERT Tiekink, MW Whitehouse. (2008) Nanogoldpharmaceutics: evaluating the response of experimentally-induced polyarthritis in rat models to colloidal gold. Metal Ions in Biology and Medicine. (Eds Collery I, Maynard T et al); 10: 556-560.
• CL Brown, MW Whitehouse, ERT Tiekink, GR Bushell. (2008) Colloidal metallic gold is not bio-inert. Inflammapharmacology. 16: 133-137.
• GG Graham, MW Whitehouse, GR Bushell. (2008) Aurocyanide, dicyano-aurate(I), a pharmacologically active metabolite of medicinal gold complexes. Inflammopharmacology. 16: 126-132.
• MW Whitehouse. (2008) Therapeutic gold: is it due for a comeback? Inflammopharmacology. 16: 107-109.
• MW Whitehouse, M Sarkar, MS Roberts. (2008) Drugs for pain and inflammation. Dermatologic, Cosmeceutic, and Cosmetic Development: therapeutic and novel approaches. (eds KA Walters, MS Roberts) New York, Informa Health Care USA Inc pp 215-241
• C Brown, G Bushell, MW Whitehouse, DS Agrawal, SG Tupe, KM Paknakar, ERT Tiekink. (2007) Nanogold pharmaceutics: (i) the use of colloidal gold to treat experimentally-induced arthritis in rat models; (ii) characterisation of the gold in Swarna bhasma, a microparticulate used in traditional Indian medicine. Gold Bulletin. 40: 245-250.
• PD Sheean, LD Hodges, N Kalafatis, PFA Wright, PM Wynne, MW Whitehouse, TA Macrides. (2007) Bioactivity of extracts from gonadal tissue of the edible Australian purple sea urchin Heliocidaris erythrogramma. J Sci Food Agric. 87: 694-702.
• MW Whitehouse. (2007) Adjuvant arthritis 50 years on (Commentary). Inflammation Res. 56: 133-138.
• Y-K Mo, O Kankavi, PP Masci, GD Mellick, MW Whitehouse, GM Boyle, PG Parsons, MS Roberts, SE Cross. (2007) Surfactant protein expression in skin: evidence and implication. J Invest Dermatol. 127: 381-386.
• Hung DY, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DHG, Roberts MS. (2006) Hepatic pharmacokinetics of Propranolol in Rats with Adjuvant-Induced Systemic Inflammation. American Journal Physiol Gastroint Liver Physiol. 290: G343-351.
• P Ghosh, S Shimmon, MW Whitehouse. (2006) Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy. Inflammapharmacology. 14: 155-162.
• KD Rainsford and MW Whitehouse. (2006) Paracetamol [acetaminophen]-induced gastrotoxicity: revealed by induced hyperacidity in combination with acute or chronic inflammation. Inflammapharmacology. 14: 150-154.
• MW Whitehouse and KD Rainsford. (2006) Lipoxygenase inhibition: the neglected frontier for regulating chronic inflammation and pain. Inflammapharmacology. 14: 99-102.
• P Ghosh, S Shimmon, M Whitehouse. (2005) The immunological basis for inflammation and cartilage destruction in osteoarthritis. New opportunities for therapeutic intervention. Reumatismo. 57: Speciale 1: 110-112.
• MW Whitehouse. (2005) Drugs to treat inflammation: a historical introduction. Current Medicinal Chemistry. 12: 2931-2942.
• MW Whitehouse. (2005) Coxibs and their aftermath: an opinionated commentary based on some historical viewpoints. Inflammapharmacology. 13: 403-417.
• MW Whitehouse. (2005) Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.  Inflammapharmacology. 12: 481-492.
• MW Whitehouse. (2005) In memory of Derek Willoughby. Inflammopharmacology. 12: 461-462.
• KA Hansford, RC. Reid, CI Clark, JDA.Tyndall, MW. Whitehouse, T Guthrie, RP McGeary, K Schafer, J L Martin, DP Fairlie*. (2003) D-Tyrosine as a Chiral Precusor to Potent Inhibitors of Human Nonpancreatic Secretory Phospholipase A2 (IIa)with Antiinflammatory Activity. ChemBioChem. 4, 181-185.
• MW Whitehouse and DE Butters. (2003) Combination anti-inflammatory therapy: synergism in rats of NSAIDs/corticosteroids with some herbal/animal products. Inflammapharmacology. 11: 453-464 .
• DE Butters and MW Whitehouse. (2003) Treating inflammation: some (needless) difficulties for gaining acceptance of effective natural products and traditional medicines. Inflammapharmacology. 11: 97-110.
• M Whitehouse. (2002) Anti-inflammatory activity of a complementary medicine (FYI). Progr.in Nutrition (Parma). 4:suppl.1: 55-61.
• MW Whitehouse. (2002) Call for a trial of Lyprinol, an over-the-counter 5-lipoxygenase inhibitor. Arthritis and Rheumatism. 46(7): 1977-1978
• MW Whitehouse, DE Butters, ML Clarke, KD Rainsford. (2001) NSAID gastropathy: prevention by celery seed extracts in disease-stressed rats. Inflammapharmacology. 9: 201-209.
• IA Shiels and MW Whitehouse. (2000) Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for Dysmenorrhoea. Allergie et Immunologie, Paris, 32: 279-283.
• SJ Harbison and MW Whitehouse. (2000) Possible steroid-sparing effect in asthma of Lyprinol, a shellfish lipid extract.  Medical Journal of Australia. 173: 560.
• SA Megwa, SE Cross, MW Whitehouse, HAE Benson, MS Roberts. (2000) Effect of ion pairing with alkylamines on the in-vitro and in-vivo dermal penetration of salicylates. : The Journal of Pharmacy and Pharmacology. 52:929-940.
• MW Whitehouse and RP McGeary. (1999) Concerning the anti-arthritic action of cetyl myristoleate in rats: an interim report. Inflammapharmacology. 7: 303-310.
• MW Whitehouse and DE Butters. (1999) Non-NSAID over-the-counter (OTC) remedies for arthritis: good, bad or indifferent? Inflammapharmacology. 7: 227-247.
• MW Whitehouse. (1999) Celery seed for arthritis.  The Herbal Doctor (Melb) 2: 9-10.
• MW Whitehouse, MS Roberts, PM Brooks (1999) Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they? Inflammapharmacology. 7: 89-105.
• DY Hung, GD Mellick, PP Masci, AN Whitaker, MW Whitehouse, MS Roberts. (1998) Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats. J.Lab.Clin.Med. 132: 469-477.
• MW Whitehouse, PD Cookson, G Siasios, ERT Tiekink. (1998) Anti-arthritic activity in rats of some phosphinegold(I) thionucleobases and related thiolates. Metal-based drugs. 5: 245-249.
• MW Whitehouse and MS Roberts (1998) Drugs for pain and inflammation. Dermal Absorption and Toxicity Assessment (Ed. MS Roberts and KA Walters) Marcel Dekker, New York: pp 327-352.
• MW Whitehouse, AG Turner, CKC Davis, MS Roberts (1998) Emu Oil(s): a source of non-toxic transdermal anti-inflammatory agents in Aboriginal medicine. Inflammopharmacology. 6: 1-8.
• MW Whitehouse, TA Macrides, N Kalafatis, WH Betts, DR Haynes, J Broadbent. (1997) Anti-inflammatory activity of a lipid fraction (Lyprinol) from the NZ green-lipped mussel. Inflammopharmacology. 5: 237-246.
• CJ van Dalen, MW Whitehouse, CC Winterbourne, AJ Kettle. (1997) Thiocyanate and chloride as competing substrates for myeloperoxidase.  Biochemistry Journal 327: 487-492.
• JM Snowden and MW Whitehouse. (1997) Anti-inflammatory action of emu oil. Inflammopharmacology. 5: 127-132.
• MW Whitehouse and GG Graham. (1996) Is local biotransformation the key to understanding the pharmacological activity of salicylates and gold drugs? Inflammation Res. 45: 579-582.
• DR Haynes, SJ Gadd, MW Whitehouse, G Mayrhofer, B Vernon-Roberts. (1996) Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporine-A and lobenzarit.  The regulation of lymph node cell populations and cytokine prodution. Inflammation Res 45: 159-165.
• MW Whitehouse. (1995) Inflammation, stress and environmental factors as determinants of NSAID efficacy and toxicity. Inflammopharmacology. 3: 373-377.
• KD Rainsford, MW Whitehouse, B Vernon-Roberts.(1995) Effects of the prostaglandin E1 analogue, misoprostol, on the development of adjuvant arthritis in rats. Inflammopharmacology. 3: 49-63.
• MW Whitehouse, D Sun, P Ghosh. (1995) A deer cartilage preparation (CervusenR) contains type II collagen and is orally active in the rat adjuvant arthritis model (Abstract).  Australian and New Zealand Journal of Medicine. 25, 400.
• MW Whitehouse, ER Tiekink, M Dekker. (1995) Gold in Medicine in Handbook of metal-ligand interactions in biological fluids (G. Berthon, Ed) New York Vol 2, 1266-1273.

Patents

• S Taylor, IA Shiels, L Brown, MW Whitehouse. (2006) Use of C-5A receptor antagonist in the treatment of fibrosis. US Patent. 10/510614.
• DE Butters, CKC Davis, RP McGeary, MC Powanda, KD Rainsford, MW Whitehouse. (2004) Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation. U.S. Patent 6352728, 5 March 2002, U.S.Patent 6576274, 10 June 2003, U.S. Patent 6791913, 13 July 2004, Au 773482.
• P Ghosh, MW Whitehouse, M Dawson, AG Turner. (1995) Anti-inflammatory composition derived from emu oil. U.S. Patent 5, 431, 922.